GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis
Europe - EPA:ALGEN - FR0004053510 - Common Stock
2.48 EUR
+0.01 (+0.4%)
Overall ALGEN gets a fundamental rating of 6 out of 10. We evaluated ALGEN against 74 industry peers in the Biotechnology industry. ALGEN has an excellent profitability rating, but there are some minor concerns on its financial health. ALGEN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ALGEN had positive earnings in the past year.
ALGEN had a positive operating cash flow in the past year.
In multiple years ALGEN reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 3.96%, ALGEN belongs to the best of the industry, outperforming 81.58% of the companies in the same industry.
With an excellent Return On Equity value of 7.06%, ALGEN belongs to the best of the industry, outperforming 82.89% of the companies in the same industry.
With an excellent Return On Invested Capital value of 6.13%, ALGEN belongs to the best of the industry, outperforming 86.84% of the companies in the same industry.
ALGEN had an Average Return On Invested Capital over the past 3 years of 5.56%. This is significantly below the industry average of 12.80%.
The last Return On Invested Capital (6.13%) for ALGEN is above the 3 year average (5.56%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROIC | 6.13% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
1.3 Margins
ALGEN has a better Profit Margin (5.86%) than 82.89% of its industry peers.
The Operating Margin of ALGEN (8.09%) is better than 82.89% of its industry peers.
ALGEN has a better Gross Margin (92.34%) than 86.84% of its industry peers.
In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
2. Health
2.1 Basic Checks
ALGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ALGEN has less shares outstanding
ALGEN has more shares outstanding than it did 5 years ago.
ALGEN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.25 indicates that ALGEN is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALGEN has a Altman-Z score of 2.25. This is in the better half of the industry: ALGEN outperforms 65.79% of its industry peers.
The Debt to FCF ratio of ALGEN is 1.41, which is an excellent value as it means it would take ALGEN, only 1.41 years of fcf income to pay off all of its debts.
ALGEN has a Debt to FCF ratio of 1.41. This is amongst the best in the industry. ALGEN outperforms 89.47% of its industry peers.
ALGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ALGEN (0.26) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Altman-Z | 2.25 |
ROIC/WACC0.87
WACC7.03%
2.3 Liquidity
A Current Ratio of 1.92 indicates that ALGEN should not have too much problems paying its short term obligations.
The Current ratio of ALGEN (1.92) is comparable to the rest of the industry.
ALGEN has a Quick Ratio of 1.81. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.
ALGEN's Quick ratio of 1.81 is in line compared to the rest of the industry. ALGEN outperforms 47.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
ALGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.41%, which is quite good.
ALGEN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.04%.
The Revenue has been growing by 18.46% on average over the past years. This is quite good.
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
3.2 Future
The Earnings Per Share is expected to decrease by 0.00% on average over the next years.
The Revenue is expected to grow by 10.37% on average over the next years. This is quite good.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 11.81, which indicates a very decent valuation of ALGEN.
Compared to the rest of the industry, the Price/Earnings ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 89.47% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of ALGEN to the average of the S&P500 Index (26.06), we can say ALGEN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.81 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 93.42% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ALGEN is valued cheaper than 94.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.19 | ||
| EV/EBITDA | 4.13 |
4.3 Compensation for Growth
The decent profitability rating of ALGEN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%
5. Dividend
5.1 Amount
ALGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALGEN (11/7/2025, 7:00:00 PM)
2.48
+0.01 (+0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners10.39%
Ins Owner ChangeN/A
Market Cap23.51M
Revenue(TTM)22.06M
Net Income(TTM)1.26M
Analysts86.67
Price Target6.02 (142.74%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.81 | ||
| Fwd PE | N/A | ||
| P/S | 1.1 | ||
| P/FCF | 5.19 | ||
| P/OCF | 3.4 | ||
| P/B | 1.32 | ||
| P/tB | 1.93 | ||
| EV/EBITDA | 4.13 |
EPS(TTM)0.21
EY8.47%
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.48
FCFY19.27%
OCF(TTM)0.73
OCFY29.38%
SpS2.26
BVpS1.88
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROCE | 7.62% | ||
| ROIC | 6.13% | ||
| ROICexc | 7.79% | ||
| ROICexgc | 11.35% | ||
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% | ||
| FCFM | 21.15% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score5
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Debt/EBITDA | 0.77 | ||
| Cap/Depr | 55.06% | ||
| Cap/Sales | 11.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 114.18% | ||
| Profit Quality | 360.76% | ||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | 2.25 |
F-Score5
WACC7.03%
ROIC/WACC0.87
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y0.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y308.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1010.09%
OCF growth 3YN/A
OCF growth 5YN/A
GENOWAY SA / ALGEN.PA FAQ
Can you provide the ChartMill fundamental rating for GENOWAY SA?
ChartMill assigns a fundamental rating of 6 / 10 to ALGEN.PA.
Can you provide the valuation status for GENOWAY SA?
ChartMill assigns a valuation rating of 5 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Fairly Valued.
How profitable is GENOWAY SA (ALGEN.PA) stock?
GENOWAY SA (ALGEN.PA) has a profitability rating of 7 / 10.
How financially healthy is GENOWAY SA?
The financial health rating of GENOWAY SA (ALGEN.PA) is 6 / 10.